Oppenheimer Maintains Outperform on HCA Healthcare, Raises Price Target to $390
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on HCA Healthcare and raises the price target from $345 to $390.
July 24, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on HCA Healthcare and raises the price target from $345 to $390.
The raised price target and maintained Outperform rating from a reputable analyst at Oppenheimer is likely to positively impact HCA Healthcare's stock price in the short term. Investors often react favorably to such updates, especially when the price target is significantly increased.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100